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When the neurogenic bladder is refractory to anticholinergics, botulinum toxin type A is used as an alternative. The neurotoxin
type A reduces bladder pressure and increases its capacity and wall compliance. Additionally, it contributes to improving urinary
continence and quality of life. This novel therapy is ambulatory with a low incidence of adverse eﬀects. Due to its transitory eﬀect,
it is necessary to repeat the injections in order to sustain its therapeutic eﬀect. In these review article we talk about Mechanism
of Action, Indications, eﬀects, administration and presentations of the Botulinum Neurotoxin Type A in pediatric patients. Also,
we make references to controversial issues surrounding its use. A bibliographic search was done selecting articles and revisions
from Pubmed. The key words used were botulinum toxin A, neurogenic bladder, and children. The search was limited to patients
younger than 18 years of age and reports written in English in the past ten years.
1.Introduction
This is a review of published work. In most cases, the neu-
rogenic bladder in children is sequela of spinal dysraphism.
Less frequent causes include sacral anomalies and traumatic
and tumoral lesions of the nervous system.
Children with open dysraphism can present diﬀerent
patterns of behavior in the lower urinary tract. In the case of
bladders with high risk of upper urinary tract deterioration,
it is essential to conﬁrm the presence of overactivity of the
detrusor muscle, with reduction in bladder capacity and
urinary incontinence; in other cases, reduced compliance
is involved. Detrusor-sphincter dyssynergia (DSD) can be
present in 50% of the cases. If it is not treated, it represents
and important risk factor, since it will naturally lead to
the development of ureterohydronephrosis in over 70% of
cases, and vesicoureteral reﬂux in 80% of cases, with renal
parenchyma deterioration [1, 2].
To achieve a urinary reservoir of adequate capacity, low
storage and voiding pressure becomes the main goal. In
this way, it is possible to preserve the upper urinary tract
undamaged. Then, the focus of attention lies on achieving
urinary continence and improving the quality of life of these
patients.
The classical treatment for the neurogenic bladder in
children consists of clean intermittent catheterization (CIC)
programs and administration of anticholinergic drugs.
Approximately, 90% of patients respond well to this type of
therapeutic scheme [3, 4]. However, a percentage of patients,
which should not be underestimated, are refractory to this
program or develop intolerance to the anticholinergic drugs
and thus require lower urinary tract reconstructions, such as
bladder augmentation, in order to achieve continent urinary
reservoirs with adequate capacity and low pressure.
Two decades ago, intravesical botulinum toxin type A
(BTX-A) was ﬁrst used as a therapeutic alternative. In 1990
it was used in adults with spinal cord injury and DSD [5].
Later on, it was expanded to patients with overactivity of the
neurogenic detrusor muscle [6].
BTX-A was not used in children with neurogenic blad-
d e r su n t i lr e c e n t l y ,b u tt o d a yi t se ﬃcacy can be conﬁrmed,
especially in the case of children with overactive detrusor.
Thus, this modality has become second-line treatment for
patients who are refractory to anticholinergic drugs [7].2 ISRN Urology
2.Pathophysiology ofDetrusorOveractivity
In healthy individuals, unmyelinated bladder aﬀerent C-
ﬁbers in the suburothelium respond at high thresholds to
mechanical stimuli, such as volume distension. On the other
hand, these ﬁbers of nociceptive nature respond only to irri-
tatingstimuli,likechemical,pH,ortemperaturechanges[8].
When there is imbalance and interruption of the aﬀerent
and eﬀerent pathways between nervous system and bladder,
the micturition reﬂex and the pathways involved are reor-
ganized, but aberrations in diﬀerent neural routes occur. In
this way, the aﬀerent C-ﬁbers can exhibit a low threshold to
mechanical stimuli, like bladder distension at low volumes,
and they can excite the spinal cord, with the subsequent
parasympathetic release of acetylcholine and erratic contrac-
tions of the detrusor muscle. This excitatory disorder is the
pathophysiologic basis of neurogenic detrusor overactivity.
The central mechanisms may also be involved in bladder
pathology. There is evidence about the eﬀects of the brain on
the bladder, especially in the social stress. The psychosocial
stressors can produce voiding dysfunctions and bladder
pathology via corticotrophin [9].
Thedisruptionofthespinobulbospinalpathwaymayalso
result in dyscoordination of the bladder-sphincter complex,
resulting in a nonrelaxing external urethral sphincter during
detrusor contraction: detrusor-sphincter dyssynergia [10].
3.BotulinumNeurotoxinType
A—Mechanism of Action
Botulinum toxin is made by the anaerobic, gram-positive
bacteria Clostridium botulinum and released as a 150-kDa
polypeptide chain. The toxin has a zinc protease that
cleaves fusion proteins and it becomes activated by selective
proteolytic cleavage to yield the heavy (100kDa) and light
(50kDa) chains that are linked by a single disulphide bond.
The heavy chain is responsible for binding to the nerve
terminal at the neuromuscular junction. The light chain,
which is internalized by endocytosis, actively cleaves a spe-
ciﬁc site on the protein complex SNAP-25 (Synaptosomal-
associated protein 25), responsible for docking and releasing
vesicles containing neurotransmitters into the neuromuscu-
lar junction. Acetylcholine is one neurotransmitter which
naturally generates muscular contraction [11]. By cleaving
protein receptors within the nerve terminals, botulinum
toxin prevents the normal vesicular transport and release of
acetylcholinefromthemotornerveterminalsintotheneuro-
muscular junction. As a consequence, muscular contractility
is eliminated causing quick relaxation and prolonged local
eﬀect. Thus, a chemical muscular denervation is achieved.
Neurotoxin A also expands its inhibitory eﬀects to sev-
eral proteins collectively called SNAREs (soluble N-ethyl-
maleimide-sensitive factor attachment protein receptors), on
which depend the release of neurotransmitters and neu-
ropeptides involved in sensory neurotransmission in re-
sponse to mechanical stimuli, such as adenosine triphos-
phate (ATP), substance P, calcitonin gene-related pep-
tide (CGRP), and glutamate. A reduction in the levels of
nerve growth factor (NGF) in the bladder wall has also
been reported. Hence, it is likely that BTX-A also modulates
intrinsic bladder reﬂexes through a multimodal eﬀect on
sensory pathways [12].
Additionally, the actions of myoﬁbroblasts located on
the suburothelium and urothelium have been studied as
elementsinvolvedinpathwaysofbladdermechanosensation.
It has been concluded that BTX-A may exert a multimodal
eﬀect on those pathways via multiple inhibition of the
vesicular release of neurotransmitters and neuropeptides
[12]. These mechanisms could explain, in part, the eﬀects
of the toxin on irritative bladder symptoms, such as voiding
urgency.
4. History—Antecedents
In1990botulinumtoxintypeAwasusedforthetreatmentof
detrusor-sphincter dyssynergia in patients with spinal cord
injury with successful results [5]. Years later, intradetrusor
BTX-A injections were used in adult patients with neuro-
genic overactivity, with encouraging results [6].
In 2002 the use of botulinum toxin was reported for
the ﬁrst time in 17 children with detrusor overactivity of
neurogenic origin. The authors concluded that BTX-A injec-
tioninpatientswithdetrusorhyperreﬂexiaincreasedbladder
capacity, reduced pressure, and improved compliance, with
good tolerance. They asserted that the use of this toxin could
become an alternative therapy to anticholinergic drugs [7].
Two years later, similar results in urodynamic parameters
were reported by Riccabona et al., but in this latter study the
impact of injections on the urinary incontinence score was
also highlighted [13].
5. Indications for PediatricPatients
These indications are as follows.
(i) Neurogenic detrusor overactivity.
(ii) Idiopathic detrusor overactivity.
(iii) Bladder overactivity syndrome.
(iv) Detrusor-sphincter dyssynergia.
(v) Reduced bladder compliance (still under revision).
6. Effects
6.1. Clinical Parameters. In patients with neurogenic bladder
that are under a clean intermittent catheterization program,
an important, although variable, reduction in incontinence
episodes has been reported. Between 65% and 85% improve-
ment in urinary continence score has been reported after
intradetrusorBTX-Ainjection[13–16].Likewise,anincrease
in urinary volumes recorded in voiding diaries was also
observed [17].
6.2. Urodynamic Variables. All the studies analyzed show
a signiﬁcant reduction in Pdetmax (maximum detrusor
pressure during bladder ﬁlling) of 33% to 55%, and inISRN Urology 3
several studies it reached values lower than 40cm H2O. The
maximum cystometric capacity increased between 35% and
80%, with basal values between 110 and 200mL. In addition,
detrusor compliance exhibited an increase between 58% and
180%. Several studies reported compliance values greater
than 20mL/cm H2O[ 13–16]. Despite the promising results
so far mentioned here, there is still a need for controlled
studies with a bigger sample size (level of evidence: 3) [18].
7. Administration of Botulinum Toxin
Type A in the Detrusor Muscle
In general, the dose used is 5 to 10U/kg of body weight;
maximum dose: 300U; dilution: 10U/mL. These values were
extrapolated from other uses of this toxin in neuropedi-
atrics. Caution should be exercised regarding the total dose
administered to children, especially when botulinum toxin
is also used to treat spasticity. In the early series, the toxin
was injected at 30 to 45 intradetrusor sites, following an
imaginary parallel line system all around the endovesical
surface, sparing the trigone, since its inclusion could increase
the possibility of generating vesicoureteral reﬂux. In recent
studies, fewer sites were injected (around 10) and they
included the trigone, with acceptable therapeutic results, like
30–45 sites [19].
The depth of the injection can be suburothelial or
intramuscular. Both techniques can increase cystometric
capacity. The technique has not been standardized. Rigid
and ﬂexible cystoscopes have been used. For the ﬂexible
cystoscope, an ultraﬁne 4mm needle (Dasgupta technique)
can be used, which is less invasive. At present, there are
no comparative studies published that analyze this aspect
of injection. There is, however, evidence of an intention to
simplify the injection technique, for instance with the use of
diﬀerent devices, such as endoinjector needle systems, with
curved needles that can reach diﬃcult endovesical sites, like
lateral walls or bladder roof and trabecular region [20, 21].
Moreover, eﬀorts to avoid the use of general anesthesia
during the injection procedure have been made. Thus,
the introduction of botulinum toxin into the detrusor by
means of 3 electrokinetic phenomena: (a) iontophoresis:
method of transmitting charged drugs though the tissue
using an electrical current; (b) electroosmosis: introduction
of nonionized molecules to the hydratation shells of ionized
particles; (c) electroporation: the permeability of the tissue is
increased[22].Thisisaneasyandsafemethodofincorporat-
ing the neurotoxin into the bladder, especially in the case of
children with neurogenic bladder due to myelomeningocele
[22] The introduction of the toxin under general anesthesia
would be reserved for adolescent patients, patients who are
anxious, patients with nonneurogenic or idiopathic bladder
dysfunction, or those with risk of autonomic dysreﬂexia.
8. BotulinumToxin TypeA Presentations
In 2009 the FDA (Food and Drug Administration) issued a
warning statement describing the diﬀerent botulinum toxins
typescurrentlyinuseinthemarketstatingthat:“Therevised
labels also emphasize that the diﬀerent botulinum toxin
products are not interchangeable, because the units used
to measure the products are diﬀerent. To help reduce the
potential for dosing errors, the botulinum toxin products
have changed their established drug names (often referred to
as the drug’s “generic” name). Neither the brand names nor
the formulations of the products have changed. Therefore,
the new names of active principles and brands are the
following:
(i) OnabotulinumtoxinA (marketed as Botox/Botox
Cosmetic).
(ii) AbobotulinumtoxinA (marketed as Dysport).
(iii) RimabotulinumtoxinB (marketed as Myobloc).
(iv) IncobotulinumtoxinA (marketed as Xeomin).”
Despite the increasing evidence for the use of BTX-A
in the urinary tract and its proven eﬃcacy, this therapeutic
alternativeiscurrentlynotlicensedforthetreatmentoflower
urinary tract and pelvic ﬂoor disorders [18]. Therefore, the
use of BTX-A in children require speciﬁc informed consent
and protocol approved by our ethical committee.
9.SpecialCases:Reduced Compliance
It has been shown that therapy with BTX-A is most eﬀective
in neurogenic bladders with overactive detrusor. This applies
tobladderswithnoninhibitedcontractionsaswellastothose
with reﬂex micturition contractions at low volumes.
Over time, compliance or wall elasticity becomes dete-
riorated in neurogenic bladders. This alteration can be
associated to overactivity of the detrusor muscle or it may
be an isolated event. It has been reported that in up to 35%
of the latter cases the bladders did not respond to BTX-A.
Hence, it could be questioned whether this lack of response
is associated to an increase in collagen tissue deposit in
the detrusor wall, especially observed in cystoscopic studies
where trabeculae and/or diverticula were found.
Paradoxically, some nonresponding patients exhibit
improvement in their micturition volumes as evidenced
in voiding diaries, and urinary continence also improves;
therefore, these patients experience substantial enhancement
in their quality of life. Moreover, the continuous subjective
improvement reported by patients or their families after 9
months of receiving botulinum toxin injections is surprising,
although these results are not reﬂected in urodynamic
parameters. This discrepancy could be explained by aﬀerent
changes triggered by diﬀerent pathways, such as suburothe-
lial aﬀerent nerves [17, 23].
Some medical teams have evaluated the possibility of
using botulinum toxin type B in cases of resistance to BTX-
A. This toxin seemed to be more eﬃcient and safer for those
patients; however, the duration of action was shorter than
that observed in patients who used BTX-A [24].
Another alternative to therapeutic resistance is to analyze
the synergy between two diﬀerent subtypes of botulinum
toxin. Nevertheless, to be able to conﬁrm these assumptions
it is necessary to design protocols with stricter criteria of
patient selection.4 ISRN Urology
10.Repeat Injections
Because the eﬀects of BTX-A in the detrusor muscle are
reversible due to nerve regeneration, repeated injections are
necessary in order to keep a sustained therapeutic eﬀect.
Grosse et al. showed that repeated injections are as eﬀective
as the ﬁrst one, when using 300U of BOTOX or 750U of
Dysport. Some patients received up to 7 repeat injections
[25]. The repetition of injections every 6 to 9 months leads
to a sustained improvement over time [15, 26]. However,
there are no studies in the literature that indicate whether
the injections should be repeated at preestablished regular
intervalsorwhenworseclinicalorurodynamicresultsappear
after an acceptable response.
It is recommended to repeat the injections no earlier
than 3 months after the ﬁrst injection, in order to avoid the
developmentofneutralizingantibodieswhichwouldattempt
against the eﬃcacy of future injections. If after the ﬁrst
two injections there is no clinical or urodynamic response,
physicians are advised against repeat injections.
11. Fibrosis
In the pediatric population, the increase of collagen deposit
in the bladder plain muscle ﬁbers is a common ﬁnding in
patients with the physiopathological congenital condition of
neurogenicbladder[27].Histologicalstudieshaveshownthe
appearance of an inﬂammatory inﬁltrate with lymphocyte
predominance and bladder wall edema after injection/s of
botulinum toxin. These ﬁndings can also be attributed to
injury of endoscopic injection.
Several studies in adults have reported on the eﬀect
of BTX-A on the detrusor wall with the use of repeated
injections.Nosigniﬁcantchangeswithrespecttothecollagen
deposit or ﬁbrosis in the detrusor before and after one
or several injections of the neurotoxin have been observed
[28, 29]. In 40 children with neurogenic bladder, after several
BTX-A intradetrusor injections, it was shown that there was
no increase of ﬁbrosis in the bladder wall, conﬁrming the
long-term safety of this treatment. In addition, with the
repeat injections a reduction in ﬁbrosis and wall trabecula-
tion was achieved. Botulinum toxin, in blocking the release
of acetylcholine, diminishes muscular contraction and the
nerve growth factor. It also inhibits release of inﬂammatory
mediators which induce ﬁbrosis [20, 21].
12. Neutralizing Antibodies
The neurotoxin causes chemical paralysis of the detrusor
muscle. The quantity of toxin that leaks into the general
blood circulation and may potentially produce antibodies
is minimum. Furthermore, most of the subjects tested
already had antitoxin antibodies before receiving the toxin;
moreover, antibodies have been found in normal control
subjects. The existence of these antibodies is explained
because some individuals with genetic predisposition had
had contact with the microorganism, which was associated
to the consumption of certain preserved food [30].
A relationship between antibodies in serum and the
lack of response to the toxin in neurogenic bladder has
been described. This lack of eﬃcacy or partial therapeutic
response has been associated with high doses of BTX-A
or its administration during short periods of time, less
than 2 months, when there are high levels of antitoxin
antibodies. Despite these ﬁndings, the increase of serum
titers is transitory and multiple injections do not stimulate
the immune system to produce neutralizing antibodies. In
thesameway,theimmunologicmemoryafterrepeatedinjec-
tions could not be proved. Nevertheless, it is recommended
that repeat injections be administered after 6 months of one
eﬀective injection in order to avoid increase of antibody
titers, anaphylactic reactions, or treatment failure [22].
13.AdverseEffects
T h eo c c u r r e n c eo fa d v e r s ee ﬀects in the use of botulinum
toxin type A accounts for less than 10% of cases. Muscular
weakness or asthenia can appear between 2 weeks and 2
months after injection. The incidence of this eﬀect lies
between 2.2% and 6%. Patients with cerebral palsy who also
receive botulinum toxin due to spasticity, or those patients
who had received high doses of the toxin are more likely to
suﬀer unwanted eﬀects [31].
Anotherpossibleeﬀectistheincreaseinpostvoidresidual
urine volume for which clean intermittent catheterization is
required transitorily. The most vulnerable populations are
patients with nonneurogenic dysfunctions or those who are
not under clean intermittent catheterization programs [32].
The combination of toxin injection into the detrusor muscle
and into the bladder neck could beneﬁt these patients.
Local eﬀects on the bladder have also been described:
hematoma at the injection site, with reported hematuria of
3.2% to 5%. Urinary tract infections vary between 6.4%
and 35%. Constipation has been reported up to 10% and
autonomic dysreﬂexia has been less frequently reported [18].
O t h e rl e s sp r o b a b l es i d ee ﬀects include: diplopy, dysphagia,
blurred vision, and Risk of respiratory depression. Eﬀects in
distant muscles and subclinical changes in respiratory heart
rate variation need for further studies on other autonomic
organs.
Botulinum toxin injection is contraindicated in those
casesin whichthe neuromuscularjunction couldbeblocked,
for example, myasthenia gravis or aminoglycoside intake.
Additionally, the use of this toxin is not recommended
in cases of bleeding diathesis, hemophilia, pregnancy, or
obstructed urinary tract.
14. FactsUp To 2011-2012
T h ef a c t sa r ea sf o l l o w s .
(i) Optimalclinicalandurodynamicresultsinoveractive
detrusor (level of evidence or LoE: 3) [18].
(ii) More knowledge about botulinum toxin therapeu-
tic eﬀects in cases of neurogenic bladder due toISRN Urology 5
myelomeningocele (93%). Other etiologies of neu-
rogenic bladder are infrequent, then the experience
with the toxin is limited.
(iii) Dosage: 5–12U/kg of body weight. Maximum dose:
300U (grade of recommendation: B) [18].
(iv) Start of therapeutic eﬀect: 2 weeks.
(v) Maximum intensity of therapeutic eﬀect: 4–6 weeks.
(vi) Duration of therapeutic action: 3–6 months. Maxi-
mum duration of action: 9–12 months.
(vii) Simultaneous injection of the toxin to the external
urethral sphincter is possible.
(viii) Improvement in intestinal function and activity of
the pelvic ﬂoor. Common neural pathway can be
responsible for the positive eﬀects in bladder and
bowel function.
(ix) Still not FDA-approved for lower urinary tract and
disorders of the pelvic ﬂoor.
15.Uncertainties
The uncertainties include the following.
(i) Which is the minimum level of bladder compliance
acceptable to be injected? The loss compliance is
related with increased connective tissue.
(ii) Can botulinum toxin be indicated in the presence of
severeurologicconditions,suchashydronephrosisor
renal disease?
(iii) Empirical use in overactive bladder syndrome; with-
out previous urodynamic studies.
(iv) What is the recommended dilution for each injec-
tion?
(v) Number of injections? Injection sites?
Better stated as current ranges with need for clariﬁcation
or testing other doses and numbers of sites.
(i) Adjuvant antimuscarinic agents?
(ii) Lowestreportedage:3yearsold(gradeofrecommen-
dation: C) [18].
16. Conclusion
Botulinum toxin type A has become a second-line treatment
for neurogenic and nonneurogenic bladder dysfunction
refractory to anticholinergic drugs. Its main beneﬁcial
eﬀects are observed in neurogenic bladders with overactivity
of the detrusor muscle, with improvement in continence
and urodynamic parameters. Moreover, the procedure of
introducing the neurotoxin into the bladder is ambulatory
and has minimal adverse eﬀects.
Nevertheless, further clinical randomized studies with
a greater number of patients, better inclusion criteria,
methods injection, and longer follow-up periods are needed
in order to optimize the levels of evidence and grades of
recommendation for the use of this toxin.
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